Compare Quest Diagnostics Inc (DGX) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Raymond James Financial, Inc. — how do they compare? Quest Diagnostics Inc trades at $206.04 (market cap $22.80B), while Raymond James Financial, Inc. trades at $171.49 (market cap $32.63B). The key difference: Raymond James Financial, Inc. is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | RJF | |
|---|---|---|
Market Cap | $22.80B | $32.63B |
Sector | Health | Financials |
52-Week High | $216.02 | $176.43 |
52-Week Low | $166.42 | $140.89 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Raymond James Financial (RJF) trades at $166.98, down 0.68% on the day, with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.83 surpassing expectations of $2.76, and revenue growth from $10.9B in 2022 to $13.84B in 2025. Analyst consensus is positive with a $176.83 price target, and recent news highlights momentum and dividend declarations.
The outlook for RJF remains favorable due to earnings momentum and analyst support, though risks include expense pressures and market volatility. Investment opportunity lies in its valuation below consensus target and dividend growth, but investors should monitor cost management and economic conditions that could impact financial services demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
